Demand's best friend: Rising pet humanisation trends have treated industry revenue with growth
Veterinary pharmaceutical manufacturers have endured their fair share of challenging trading conditions. Demand from downstream beef, cattle and sheep farming has been volatile thanks to seasonal weather patterns that battered farmers with either prolonged drought conditions or escalating flood waters. Livestock numbers fell in the face of these extreme conditions and with-it tumbled demand for veterinary pharmaceuticals. Stringent regulatory controls, higher compliance costs and growing consolidation pressures have compounded this issue, prompting several major global pharmaceutical companies to divest their animal health pharmaceutical operations.
Industry firms manufacture drugs, medicines, medicinal chemicals, vaccines, serums and other pharmaceutical products for veterinary use. These animal health products are targeted towards food-producing animals (cattle, pigs, poultry and sheep) and companion animals (primarily dogs and cats).
This report covers the scope, size, disposition and growth of the industry including the key sensitivities and success factors. Also included are five year industry forecasts, growth rates and an analysis of the industry's key players and their market shares.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Virbac (Australia) Pty Limited
- Zoetis Australia Pty Ltd
- Intervet Schering-Plough Animal Health Pty Ltd
Methodology
LOADING...
